NaturalShrimp Announces Filing of Joint Patent Application
NaturalShrimp Announces Filing of Joint Patent Application
Strengthens Intellectual Property (IP) Protection Related to Electrocoagulation (EC) and HydroGas Technologies
加强与电凝聚(EC)和氢气技术相关的知识产权(IP)保护
DALLAS, TX, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), and its technology partner, Hydrenesis, Inc., today announced the filing a United States joint patent application to further strengthen the Intellectual
达拉斯，德克萨斯州，2022年10月6日(Global Newswire)--Via NewMediaWire-NaturalShrimp，Inc.(OTCQB：SHMP)是一家生物技术水产养殖公司，已经开发并获得了第一个以虾为中心的商业操作RAS(循环水产养殖系统)并获得了专利，它的技术合作伙伴Hydrenesis，Inc.今天宣布提交一项美国联合专利申请，以进一步加强对虾的智力
Property (IP) protection related to Electrocoagulation (EC) and HydroGas technologies.
与电凝聚(EC)和氢气技术相关的财产(IP)保护。
EC and Hydrogas have shown efficacy in improving welfare scores not only in shrimp production, but also in finfish, as evidenced by third party trials conducted at a leading aquaculture testing facility in Bergen, Norway. The newly filed patent application involves technology co-developed by NaturalShrimp and Hydrenesis as a strategy to augment existing IP protection with additional, and more advanced methods and apparatus. NaturalShrimp will license the EC and HydroGas technologies for various aquatic species.
欧共体和氢化气不仅在对虾生产方面，而且在在挪威卑尔根的一家领先的水产养殖测试设施进行的第三方试验中，都显示出提高福利分数的有效性。新提交的专利申请涉及NaturalShrimp和Hydrenesis共同开发的技术，作为一种战略，用更多和更先进的方法和设备来加强现有的知识产权保护。NaturalShrimp将为各种水生物种授权EC和Hapor Gas技术。
"We are constantly looking for ways to improve efficiency and broad applications for our technologies, not just in shrimp, but also in additional aquatic species," said Tom Untermeyer, Chief Operations Officer and Chief Technology Officer. "Our work with Hydrenesis to develop the new technologies has strengthened our engineering capabilities, and we look forward to ongoing co-development work with Hydrenesis to enhance our IP portfolio even further."
首席运营官兼首席技术官汤姆·昂特迈尔说，我们一直在寻找提高效率的方法，并将我们的技术广泛应用于其他水生物种，不仅是虾，还有其他水生物种。我们与Hydrenesis公司合作开发新技术增强了我们的工程能力，我们期待着与Hydrenesis公司继续共同开发工作，以进一步增强我们的知识产权组合。“
Gerald Easterling, Chief Executive Officer, added, "As we continue to expand our shrimp production capabilities, having additional IP such as this will only strengthen our presence both domestically and internationally, as we expand over the next several years."
首席执行官杰拉尔德·伊斯特林补充说：“随着我们继续扩大我们的对虾生产能力，拥有这样的额外知识产权只会加强我们在国内和国际上的存在，因为我们将在未来几年扩大规模。”
David Antelo, Hydrenesis President and CEO, also added, "The cohesive relationship between the NaturalShrimp and Hydrenesis engineering teams has accelerated the development of our technologies as we focus on an aggressive growth trajectory. This joint patent represents more than 12 months of collaboration and is expected to add shareholder value as the commercialization phases unfold."
Hydrenesis总裁首席执行官兼首席执行官戴维·安特洛也补充道：“NaturalShrimp和Hydrenesis工程团队之间的紧密联系加速了我们技术的发展，因为我们专注于积极的增长轨迹。这项联合专利代表着12个多月的合作，随着商业化阶段的展开，预计将增加股东价值。”
About NaturalShrimp
关于天然虾
NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit .
NaturalShrimp，Inc.是一家上市水产养殖公司，总部设在达拉斯，生产设施位于德克萨斯州圣安东尼奥和爱荷华州韦伯斯特市附近。该公司开发了第一个商业上可行的系统，用于在封闭的咸水系统中种植虾，使用专利技术生产新鲜的、从未冷冻的自然生长的虾，而不使用抗生素或有毒化学品。NaturalShrimp系统可以分布在世界任何地方，生产美食级的太平洋白虾。有关更多信息，请访问。
Forward-Looking Statements
前瞻性陈述
This press release contains a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, any of which may cause our company's or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
本新闻稿包含许多前瞻性陈述，反映管理层对未来事件和财务业绩的当前看法。前瞻性陈述是对未来事件或我们未来财务表现的预测。在某些情况下，您可以通过“可能”、“应该”、“预期”、“计划”、“预期”、“相信”、“估计”、“预测”、“可能”或“继续”等术语或这些术语或其他类似术语的负面含义来识别前瞻性陈述。这些陈述包括关于我们和我们管理团队成员的意图、信念或当前期望的陈述，以及此类陈述所基于的假设。提醒潜在投资者，任何此类前瞻性陈述都不是对未来业绩的保证，涉及风险和不确定因素，实际结果可能与此类前瞻性陈述中预期的大不相同。这些陈述只是预测，涉及已知和未知的风险、不确定因素和其他因素，包括公司在截至2021年3月31日的财政年度的10-K表格年度报告中“风险因素”一节所阐述的风险，任何这些风险都可能导致我们公司或我们行业的实际结果、活动水平、业绩或成就与我们的前瞻性陈述中明示或暗示的任何未来结果、活动水平、表现或成就大不相同。
Investor Relations Contact
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
SHMP@mzgroup.us
投资者关系联系人
克里斯·泰森
总裁常务副总经理
MZ北美
直拨：949-491-8235
邮箱：shmp@mzgroup.us